Idifarma Launches New Service for Accelerated Clinical Pathway

CDMO Idifarma has launched a new service aimed at delivering an accelerated pathway for complex drugs.

Idifarma, a contract development and manufacturing organization (CDMO), has launched a new service aimed at delivering an accelerated pathway for complex drugs. The launch was announced in a July 14, 2021 press release.

The new service, Simply to Clinic, takes drug projects from pre-formulation to clinical trial implementation guided by Idifarma’s expertise in oral standard and highly potent drugs. Customers can receive tailored services in the development, scale-up, and manufacture of the product at Idifarma’s facility in Pamplona, Spain.

“The technologies and expertise gained by Idifarma across its support of clinical trials of spray dried and oral solid dosage forms for more than 20 years provides the strong foundation needed for this service,” said Idifarma’s head of site, Alfredo Gómez, in the press release. “Innovative products and clinical trials are often complicated because of timelines, regulations, and the use of highly potent active substances. We truly believe that Simply to Clinic will provide many pharma companies with a quick and smooth entry into the challenging clinical program of new drugs. We are experienced in the problems commonly faced and will offer ourintegrated services to achieve a successful, timely, and cost-effective outcome.”

Source: Idifarma